$PFE

Buckley Mortimer J purchased $960K of PFE

Buckley Mortimer J purchased 37,632 shares of PFIZER INC (PFE) at $25.52 ($0.96M total) on 2026-08-05.

Original reporting
SEC EDGAR · Buckley Mortimer J
Published Aug 5, 2026, 4:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 6, 2026, 6:27 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PFE
Neutral
medium confidence
Mentioned
$PFE
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFENeutralLow
01

Why it matters

A director open-market purchase is incremental sentiment information, not a new fundamental driver.

02

Market read

Traders may note the insider buy, but there is no accompanying guidance, legal, regulatory, or operational update.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan, but it still does not reveal intent, timing constraints, or whether the purchase is meaningful versus prior activity.

Relevance 6/10Novelty 4/10Timing: filed 2026-08-05, after-hours/late session disclosure

Background

The article is a SEC Form 4 insider transaction disclosure for Pfizer Inc.

Company-level read

Ticker impact

$PFENeutralMedium confidence
Context

Pfizer director Buckley Mortimer J bought 37,632 shares in an open-market transaction on 2026-08-05 for about $960K.

Expected impact

Likely limited near-term impact; may modestly support sentiment but is usually not trade-driving alone.

Evidence & confidence

Form 4 insider purchases can be read as confidence signals, yet the filing provides no new company-specific operational or financial information.

Market effects

No direct sector read-through; this is company-specific insider activity without broader industry news.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine, tax-related, or part of personal liquidity planning, so the signal may be weak.

Key entities

  • Pfizer Inc

    Subject of the Form 4 insider transaction disclosure.

  • Buckley Mortimer J

    Director who purchased 37,632 shares on 2026-08-05.

Related articles

$PFEMed

PFE builds bull case at $26 after earnings beat and insider buys

Pfizer (PFE) shares trade near $26.20 after its Q2 beat on Aug 4. Adjusted EPS was $0.77 vs $0.68 consensus, and revenue was $15.03B vs $14.41B. Pfizer raised 2026 revenue guidance to $60.5B-$62.5B and added $2.5B cost savings (total $9.7B by 2029). Board directors bought about $1M each; bulls cite a base around $24-$26, bears cite patent-cliff revenue risk.

$PFEMedAI 8/10

Pfizer Stock Slips Despite Earnings Beat and $2.5 Billion Cuts

Pfizer (PFE) shares fell about 0.5% early despite an earnings beat and a higher revenue outlook. Adjusted EPS was $0.77, above estimates by $0.09. Pfizer announced another $2.5B cost reduction, raising savings through 2029 to $9.7B. Eliquis revenue rose 21% to $2.43B and Padcev rose 23% to $667M. Full-year revenue guidance was raised to $60.5B-$62.5B; adjusted EPS guidance stayed $2.80-$3.00.

$PFEMed

Pfizer Q2 Earnings Call Highlights

Pfizer’s Q2 earnings call covered COVID vaccine and PAXLOVID revenue sensitivity, margin and expense trends, and a GAAP loss per share of $0.04 driven by $4.3B non-cash impairments. Pfizer raised cost-savings expectations to about $9.7B net through 2029, reported $3.45B operating cash flow, and said it will maintain its dividend. Pipeline updates included PADCEV, prostate and obesity programs.